2023
α1 Adrenoreceptor antagonism mitigates extracellular mitochondrial DNA accumulation in lung fibrosis models and in patients with idiopathic pulmonary fibrosis
Ishikawa G, Peng X, McGovern J, Woo S, Perry C, Liu A, Yu S, Ghincea A, Kishchanka A, Fiorini V, Hu B, Sun Y, Sun H, Ryu C, Herzog E. α1 Adrenoreceptor antagonism mitigates extracellular mitochondrial DNA accumulation in lung fibrosis models and in patients with idiopathic pulmonary fibrosis. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2023, 324: l639-l651. PMID: 36648147, PMCID: PMC10110730, DOI: 10.1152/ajplung.00119.2022.Peer-Reviewed Original ResearchConceptsAdrenergic nerve supplyIdiopathic pulmonary fibrosisΑ1 adrenoreceptorsPulmonary fibrosisNerve supplyCultured normal human lung fibroblastsInnate immune ligandsLung fibrosis modelNormal human lung fibroblastsSmooth muscle actinHuman lung fibroblastsAdrenal resectionAdrenoreceptor antagonismExtracellular mtDNAIPF cohortImproved survivalΑ1-adrenoreceptor antagonistsLung fibrosisAdrenal sourceFibroblast accumulationAdrenoreceptor antagonistBleomycin modelFibrosis modelLung fibrogenesisMouse model
2022
PTX3 in Granuloma Formation and Sarcoidosis: Helping Macrophages Accept a “Complement”
Ishikawa G, Herzog EL. PTX3 in Granuloma Formation and Sarcoidosis: Helping Macrophages Accept a “Complement”. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 1064-1065. PMID: 35820078, PMCID: PMC9704837, DOI: 10.1164/rccm.202207-1277ed.Commentaries, Editorials and Letters
2019
Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia
Ishikawa G, Fujiwara N, Hirschfield H, Varricchio L, Hoshida Y, Barosi G, Rosti V, Padilla M, Mazzarini M, Friedman SL, Hoffman R, Migliaccio AR. Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. Experimental Hematology 2019, 79: 16-25.e3. PMID: 31678370, PMCID: PMC6910948, DOI: 10.1016/j.exphem.2019.10.001.Peer-Reviewed Original ResearchConceptsBone marrowLung fibrosisMyeloproliferative neoplasmsEssential thrombocytopeniaLiver fibrosisPhiladelphia-negative myeloproliferative neoplasmsProtein 1Possible therapeutic targetPrimary myelofibrosis patientsExpression of Id1Extracellular matrix protein 1Poor prognosisIL-8Myelofibrosis patientsEssential thrombocythemiaTherapeutic targetPrimary myelofibrosisFibrosisMegakaryocyte hyperplasiaCholesterol homeostasisBM functionHematopoietic failureMatrix protein 1K-rasPotential targetConcomitant Interstitial Lung Disease with Psoriasis
Ishikawa G, Dua S, Mathur A, Acquah SO, Salvatore M, Beasley MB, Padilla ML. Concomitant Interstitial Lung Disease with Psoriasis. Canadian Respiratory Journal 2019, 2019: 5919304. PMID: 31534591, PMCID: PMC6732645, DOI: 10.1155/2019/5919304.Peer-Reviewed Original ResearchConceptsNonspecific interstitial pneumoniaPneumonia patternConcomitant diagnosisConcomitant interstitial lung diseaseInterstitial lung disease patientsUsual interstitial pneumonia patternChronic hypersensitivity pneumonitisLung disease patientsCryptogenic organizing pneumoniaFurther prospective studiesIdiopathic pulmonary fibrosisInterstitial lung diseaseInterstitial pneumonia patternMount Sinai HospitalConcomitant psoriasisNSIP patternILD patientsImmunosuppressive therapyOrganizing pneumoniaInterstitial pneumoniaMedian ageRetrospective reviewCase seriesPulmonary fibrosisHypersensitivity pneumonitis
2018
Is It Idiopathic Pulmonary Fibrosis or Not?
Salvatore M, Ishikawa G, Padilla M. Is It Idiopathic Pulmonary Fibrosis or Not? The Journal Of The American Board Of Family Medicine 2018, 31: 151-162. PMID: 29330249, DOI: 10.3122/jabfm.2018.01.170288.Peer-Reviewed Original ResearchConceptsUsual interstitial pneumonitisPulmonary fibrosisInterstitial pneumonitisCorrect diagnosisAccurate diagnosisUIP/IPFChronic hypersensitivity pneumonitisIdiopathic pulmonary fibrosisNonspecific interstitial pneumonitisPulmonary fibrotic diseasesAmerican Thoracic SocietyAntifibrotic medicationsFibrotic sarcoidosisMean life expectancySerologic testingWorse prognosisCareful historyHypersensitivity pneumonitisThoracic SocietyFibrotic pathwaysInvasive proceduresClinician's abilityFibrotic diseasesPneumonitisFibrosis
2017
Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease
Ishikawa G, Acquah SO, Salvatore M, Padilla ML. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease. Respiratory Medicine 2017, 128: 78-84. PMID: 28610674, DOI: 10.1016/j.rmed.2017.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlveolitis, Extrinsic AllergicBiomarkersChronic DiseaseDisease ProgressionFemaleFibrin Fibrinogen Degradation ProductsHospitalizationHumansIdiopathic Interstitial PneumoniasIdiopathic Pulmonary FibrosisL-Lactate DehydrogenaseLung Diseases, InterstitialMaleMiddle AgedMortalityOutcome Assessment, Health CarePredictive Value of TestsPrognosisPulmonary EmphysemaRetrospective StudiesRisk FactorsVenous ThromboembolismConceptsElevated serum D-dimer levelsSerum D-dimer levelsInterstitial lung diseaseD-dimer levelsAcute exacerbationRespiratory-related hospitalizationsSerum D-dimerD-dimer measurementVenous thromboembolismCause hospitalizationCause mortalityD-dimerLung diseaseOutcome measuresElevated serum D-dimerCollagen tissue diseasesSubsequent acute exacerbationChronic hypersensitivity pneumonitisSecondary outcome measuresHome oxygen therapyIdiopathic interstitial pneumoniaIdiopathic pulmonary fibrosisPrimary outcome measureSerum lactate dehydrogenaseInterstitial pneumonia